Moore Jason N, Healy Jason R, Kraft Walter K
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South Tenth Street, Main Building, Room 1170, Philadelphia, PA 19107, USA.
Expert Rev Clin Pharmacol. 2015 May;8(3):321-34. doi: 10.1586/17512433.2015.1034689.
Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral tablet and intravenous solution formulations provide an attractive treatment option by reducing interpatient variability and providing flexibility in critically ill patients. On the basis of clinical experience and further clinical studies, posaconazole was found to be a valuable pharmaceutical agent for the treatment of life-threatening fungal infections. This review will examine the development history of posaconazole and highlight the most recent advances.
泊沙康唑是一种广谱三唑类抗真菌药物，除了用于治疗口咽念珠菌病外，还被批准用于预防侵袭性曲霉病和念珠菌病。有证据表明其在治疗和预防罕见且更难治疗的真菌感染方面具有疗效。泊沙康唑口服混悬液在禁食状态下的吸收、胃肠道pH值升高和蠕动增加方面存在局限性。新批准的缓释口服片剂和静脉溶液制剂通过减少患者间变异性并为重症患者提供灵活性，提供了一种有吸引力的治疗选择。基于临床经验和进一步的临床研究，发现泊沙康唑是治疗危及生命的真菌感染的一种有价值的药物。本综述将考察泊沙康唑的发展历程，并突出其最新进展。
